Butyrate Reduces Sympathetic Activation in Heart Failure Rats
Author Information
Author(s): Liu Chang, Yu Hao, Xia Hongyi, Wang Ziwei, Li Bolin, Xue Hongmei, Jin Sheng, Xiao Lin, Wu Yuming, Guo Qi
Primary Institution: Hebei Medical University
Hypothesis
The intestinal metabolite butyrate reduces sympathetic activation in rats with heart failure and the underlying mechanisms involved.
Conclusion
Butyrate improves cardiac function and reduces sympathetic activation in rats with heart failure by enhancing intestinal barrier function and decreasing microglial inflammation.
Supporting Evidence
- Cardiac function improved in HF rats treated with butyrate, with ejection fraction increasing from 22.6% to 38.3%.
- Sympathetic activation decreased in HF rats treated with butyrate, with renal sympathetic nerve activity dropping from 36.3% to 23.9%.
- Plasma norepinephrine levels decreased in HF rats treated with butyrate.
Takeaway
Butyrate, a substance made by gut bacteria, helps heart failure rats feel better by calming their nerves and fixing their gut.
Methodology
The study used a rat model of heart failure induced by ligation of the left anterior descending artery, with treatment involving butyrate sodium for 8 weeks.
Limitations
The study did not provide direct evidence that sympathetic activation leads to gut dysfunction in heart failure or is the target of butyrate.
Participant Demographics
Male Sprague-Dawley rats weighing 220-250 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website